FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the Company has secured payer contracts with national provider networks MultiPlan, Inc., FedMed, Inc. and Preferred Medical Claim Solutions, LLC to provide coverage of its DecisionDx™ assays. These networks together provide access to more than 120 million covered lives.
“These new agreements reflect the growing clinical adoption of our portfolio of evidence-based diagnostic test services. Many more patients and their physicians can now gain critical insight into their specific tumor biology to make more informed treatment decisions,” said Derek Maetzold, President and CEO of Castle Biosciences. “We continue to develop additional tests in disease areas where molecular information could significantly impact patient outcomes and become standard of care.”
Castle Biosciences’ first widely adopted gene expression profile test, DecisionDx™-UM, is the standard of care prognostic tool for uveal (ocular) melanoma and serves as the model for its growing lineup of practice-changing tests. The Company’s first internally discovered and validated test, DecisionDx™-Melanoma, analyzes the activity of specific genes within a cutaneous (skin) melanoma tumor to predict an individual patient’s risk of metastatic disease, independent of traditional staging modalities. To date, the DecisionDx-Melanoma test’s accuracy has been clinically validated in three multi-center studies using over 600 archived melanoma tumor samples, with data recently published in the Journal of the American Academy of Dermatology and Clinical Cancer Research. Castle Biosciences also offers prognostic tests in other critical areas of high unmet need, including esophageal cancer, mesothelioma and glioblastoma multiforme.
About Castle Biosciences
Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma (DecisionDx™-UM), cutaneous melanoma (DecisionDx™-Melanoma) and esophageal cancer (DecisionDx™-EC), among others. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.castlebiosciences.com.
DecisionDx™-UM, DecisionDx™-Melanoma and DecisionDx™-EC are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.